Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Brigimadlin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Go deeper with GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brigimadlin overview
Brigimadlin (BI-907828) is under development for the treatment of solid tumors including melanoma, gastric cancer, bladder cancer, bile duct cancer (cholangiocarcinoma), extrahepatic bile duct cancer, gallbladder cancer, liposarcoma, advanced dedifferentiated liposarcoma, hepatocellular carcinoma, glioblastoma multiforme (GBM), non-small cell lung cancer, lung adenocarcinoma, colon cancer, soft tissue sarcoma, synovial sarcoma, leiomyosarcoma, metastatic biliary tract cancer, transitional cell carcinoma (urothelial cell carcinoma), pancreatic ductal adenocarcinoma, triple negative breast cancer, metastatic colorectal cancer and brain metastases. The drug candidate is a film-coated tablet administered by the oral route. The drug candidate acts by targeting MDM2-p53. It was also under development for colon cancer.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
For a complete picture of Brigimadlin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
